Evidence map›Paper›PMID 30346998›Full record

ArticlePloS one2018

Aerosol prime-boost vaccination provides strong protection in outbred rabbits against virulent type A Francisella tularensis.

Katherine J O'Malley, Jennifer D Bowling, Elizabeth Stinson, Kelly S Cole, Barbara J Mann, Prachi Namjoshi, Karsten R O Hazlett, Eileen M Barry, Douglas S Reed

Erratum issuedOpen access · goldAbstract read
In one paragraph

Article in PloS one, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.7field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 12 citations in OpenAlex.

  1. The rLVS ΔHuman vaccines & immunotherapeutics · 2023
    Article
  2. Article
  3. Identification of an Attenuated Substrain ofPathogens (Basel, Switzerland) · 2021
    Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 1 country.

Katherine J O'MalleyCenter for Vaccine Research, University of Pittsburgh, Pittsburgh, PA, United States of America.
Jennifer D BowlingCenter for Vaccine Research, University of Pittsburgh, Pittsburgh, PA, United States of America.ORCID 0000-0002-1432-0211
Elizabeth StinsonCenter for Vaccine Research, University of Pittsburgh, Pittsburgh, PA, United States of America.
Kelly S ColeCenter for Vaccine Research, University of Pittsburgh, Pittsburgh, PA, United States of America.
Barbara J MannDepartment of Medicine, Division of Infectious Diseases and International Health, University of Virginia, Charlottesville, VA, United States of America.ORCID 0000-0002-5549-2562
Prachi NamjoshiDepartment for Immunology & Microbial Diseases, Albany Medical College, Albany, NY, United States of America.
Karsten R O HazlettDepartment for Immunology & Microbial Diseases, Albany Medical College, Albany, NY, United States of America.
Eileen M BarryCenter for Vaccine Development, University of Maryland Baltimore, Baltimore, MD, United States of America.
Douglas S ReedCenter for Vaccine Research, University of Pittsburgh, Pittsburgh, PA, United States of America.ORCID 0000-0003-0076-9023
University of Pittsburgh · USAlbany Medical Center Hospital · USUniversity of Maryland, Baltimore · USUniversity of Virginia · US

Funding

Correlates of Vaccine-Induced, Tunable-Protection in an Outbred Tularemia ModelR01AI123129 · NIAID · ALBANY MEDICAL COLLEGE · PI BARRY, EILEEN M., HAZLETT, KARSTEN R.O. · 2016 to 2020
$3.7M
Criteria-Directed Vaccine Generation Via Ag Mimicry, Adjuvancy, And APC-TargetingR01AI100138 · NIAID · ALBANY MEDICAL COLLEGE · PI GOSSELIN, EDMUND J, HAZLETT, KARSTEN R.O. · 2013 to 2017
$2.9M
Advancement of a Defined, Protective, Live Attenuated Tularemia VaccineR01AI102966 · NIAID · UNIVERSITY OF MARYLAND BALTIMORE · PI BARRY, EILEEN M. · 2013 to 2015
$2.1M
Advancement of New Live Attenuated F. Tularensis Type A Vaccine StrainsU01AI077909 · NIAID · UNIVERSITY OF MARYLAND BALTIMORE · PI BARRY, EILEEN M. · 2009 to 2010
$1.1M
NIAID NIH HHS R01 AI100138NIAID NIH HHS R01 AI102966NIAID NIH HHS R01 AI123129NIAID NIH HHS U01 AI077909
6 · The paper itself

Abstract

Tularemia, also known as rabbit fever, is a severe zoonotic disease in humans caused by the gram-negative bacterium Francisella tularensis (Ft). While there have been a number of attempts to develop a vaccine for Ft, few candidates have advanced beyond experiments in inbred mice. We report here that a prime-boost strategy with aerosol delivery of recombinant live attenuated candidate Ft S4ΔaroD offers significant protection (83% survival) in an outbred animal model, New Zealand White rabbits, against aerosol challenge with 248 cfu (11 LD50) of virulent type A Ft SCHU S4. Surviving rabbits given two doses of the attenuated strains by aerosol did not exhibit substantial post-challenge fevers, changes in erythrocyte sedimentation rate or in complete blood counts. At a higher challenge dose (3,186 cfu; 139 LD50), protection was still good with 66% of S4ΔaroD-vaccinated rabbits surviving while 50% of S4ΔguaBA vaccinated rabbits also survived challenge. Pre-challenge plasma IgG titers against Ft SCHU S4 corresponded with survival time after challenge. Western blot analysis found that plasma antibody shifted from predominantly targeting Ft O-antigen after the prime vaccination to other antigens after the boost. These results demonstrate the superior protection conferred by a live attenuated derivative of virulent F. tularensis, particularly when given in an aerosol prime-boost regimen.

Indexed as

Immunization, SecondaryVaccinationAerosolsAnimalsAnimals, Outbred StrainsAntibodies, BacterialBacterial VaccinesBlood SedimentationDose-Response Relationship, ImmunologicFrancisella tularensisImmunoglobulin GRabbitsSurvival AnalysisTularemiaVirulenceWeight LossAerosolsAntibodies, BacterialBacterial VaccinesImmunoglobulin G

Identifiers

PMID30346998
PMCPMC6197691
OpenAlexW2896478738

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.